Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: Pharmacological and clinical aspects;Le tamoxifène et les inhibiteurs d'aromatase dans le traitement des cancers du sein: Aspects pharmacologiques et cliniques

Bulletin du Cancer

Volumn 91, Issue 12, 2004, Pages 917-927

  De Cremoux, Patricia ^a   Diéras, Veronique ^a   Poupon, Marie France ^a   Magdelénat, Henri ^a   Sigal Zafrani, Brigitte ^a   Fourquet, Alain ^a   Pierga, Jean Yves ^a  

^a INSTITUT CURIE   (France)

Author keywords

Anti aromatase; Aromatase; Breast carcinoma; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMASINE; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 3A4; EPIDERMAL GROWTH FACTOR; ESTROGEN; EXEMESTANE; FORMESTANE; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; STEROID 17ALPHA MONOOXYGENASE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA;

ARTHRALGIA; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; ENDOMETRIUM CANCER; ENZYME INHIBITION; ESTROGEN METABOLISM; FRACTURE; HUMAN; LEUKORRHEA; MENOPAUSE; MYALGIA; POSTMENOPAUSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; UTERUS CANCER; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MENOPAUSE; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRIAZOLES;

EID: 12844262762     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-7.
2. Jensen EV, Suzuki T, Kawashima T, Stumpf WE, Jungblut PW, DeSombre ER. A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci USA 1968; 59(2): 632-8.
3. Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971; 34: 55-70.
4. McGuire WL, Osborne CK, Clark GM, Knight 3rd WA. Steroid hormone receptors and carcinoma of the breast. Am J Physiol 1982; 243: E99-E102.
5. Miller W, O'Neill J. The importance of local synthesis of estrogen within the breast. Steroids 1987; 50: 537-48.
6. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-70.
7. Menasce LP, White GR, Harrison CJ, Boyle JM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993; 17: 263-5.
8. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258-65.
9. Tsai MJ, O'Malley BW. Molecular mechanisms of acrion of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451-86.
10. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 1997; 272: 19858-62.
11. Pettersson K, Grandien K, Kuiper GG, Gustafsson JA. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol Endocrinol 1997; 11: 1486-96.
12. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-8.
13. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999; 20: 321-44.
14. Smith CL, Nawaz Z, O'Malley BW. Coaccivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997; 11: 657-66.
15. Norris JD, Paige LA, Christensen DJ, et al. Peptide antagonists of the human estrogen receptor. Science 1999; 285: 744-6.
16. Kuiper GG, Gustafsson JA. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 1997; 410: 87-90.
17. McDonnell DP, Connor CE, Wijayaratne A, Chang CY, Norris JD. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog Horm Res 2002; 57: 295-316.
18. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566-78.
19. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001; 53: 25-71.
20. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev Cancer 2002; 2: 101-12.
21. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001; 61: 5683-7.
22. Jepsen K, Hermanson O, Onami TM, et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 2000; 102: 753-63.
23. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA 1999; 96: 6947-52.
24. Oestetreich S, Zhang Q, Hopp T, et al. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol 2000; 14: 369-81.
25. Osborne CK, Boldt DH, Clark GM, Trent JM. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 1983; 43: 3583-5.
26. Wakeling AE, Newboult E, Peters SW. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J Mol Endocrinol 1989; 2: 225-34.
27. Musgrove EA, Wakeling AE, Sutherland RL. Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res 1989; 49: 2398-404.
28. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-28.
29. Butta A, MacLennan K, Flanders KC, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4.
30. Winston R, Kao PC, Kiang DT. Regulation of insulin-like growth factors by antiestrogen. Breast Cancer Res Treat 1994; 31: 107-15.
31. Jordan VC, Robinson SP. Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc 1987; 46: 1870-4.
32. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88.
33. Liu X, Pisha E, Tonetti DA, et al. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chem Res Toxicol 2003; 16: 832-7.
34. Love RR, Koroltchouk V. Tamoxifen therapy in breast cancer control worldwide. Bull World Health Organ 1993; 71: 795-803.
35. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000; 18: 3172-86.
36. Diez JL. Skeletal effects of selective oestrogen receptor modulators (SERMs). Hum Reprod Update 2000; 6: 255-8.
37. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151-96.
38. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003; 42: 361-72.
39. Taras TL, Wurz GT, Linares GR, DeGregorio MW. Clinical pharmacokinetics of toremifene. Clin Pharmacokinet 2000; 39: 327-34.
40. Evans CT, Ledesma DB, Schulz TZ, Simpson ER, Mendelson CR. Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. Proc Natl Acad Sci USA 1986; 83: 6387-91.
41. Dowsett M. Efforts to link biological and clinical breast cancer research. Breast 2003; 12: 442-6.
42. Miller WR, Hawkins RA, Forrest AP. Significance of aromatase activity in human breast cancer. Cancer Res 1982; 42(8 Suppl): 3365s-3368s.
43. de Jong PC, Blankenstein MA, Van de Ven J, Nortier JW, Blijham GH, Thijssen JH. Importance of local aromatase activity in hormone-dependent breast cancer: a review. Breast 2001; 10: 91-9.
44. Miller WR. Aromatase and its inhibitors: new biology and clinical perspectives. Endocr Relat Cancer 1999; 6: 127-30.
45. Bulun SE, Sharda G, Rink J, Sharma S, Simpson ER. Distribution of aromatase P45O transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metab 1996; 81: 1273-7.
46. Schwarzel WC, Kruggel WG, Brodie HJ. Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta. Endocrinology 1973; 92: 866-80.
47. Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nature Rev Cancer 2003; 3: 821-31.
48. Evans TR. Clinical applications of new aromatase inhibitors. Crit Rev Oncol Hematol 1994; 16: 129-43.
49. Lipton A, Santen RJ. Proceedings: Medical adrenalectomy using amino-glutethimide and dexamethasone in advanced breast cancer. Cancer 1974; 33: 503-12.
50. Brodie AM, Njar VC. Aromatase inhibitors and breast cancer. Semin Oncol 1996; 23(4 Suppl 9): 10-20.
51. Njar VC, Brodie AM. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 1999; 58: 233-55.
52. Namer M. Aromatase inhibitors: therapeutic outlook. Bull Cancer 2000; 87(Spec): 41-5.
53. Sinha S, Kaseta J, Santner SJ, Demers LM, Bremmer WJ, Santen RJ. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat 1998; 48: 45-51.
54. de Cremoux P. Aromatase inhibitors: pharmacological aspects. Bull Cancer 2000; 87(Spec): 23-9.
55. Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 2003; 9(1 Pt 2): 468S-472S.
56. Lonning P, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol 2003; 30(4 Suppl 14): 23-32.
57. Yates RA, Wong J, Seiberling M, Merz M, Marz W, Nauck M. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 2001; 51: 429-35.
58. Brueggemeier RW. Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res Treat 2002; 74: 177-85.
59. ATAC's trialist group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-9.
60. Ingle JN, Suman VJ, Jordan VC, Dowsett M. Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer. Endocr Relat Cancer 1999; 6: 265-9
61. Dowsett M, Smith IE, trialists I. Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) than with tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: a potential predictor of relapse-free survival. Breast Cancer Res Treat 2003; 82: S6.
62. Rivera E, Valero V, Francis D, et al. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 2004; 10: 1943-8.
63. Schmid P, Possinger K. Interactions of antioestrogens and aromatase inhibitors. Forum (Genova) 2002; 12: 45-59.
64. Lonning PE. Cross-resistance to different aromatase inhibitors in breast cancer treatment. Endocr Relat Cancer 1999; 6: 251-7.
65. Come SE, Buzdar AU, Arteaga CL, et al. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res 2003; 9(1 Pt 2): 443S-446S.
66. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-606.
67. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-9.
68. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-67.
69. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-58.
70. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-57.
71. Thurlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003; 39: 2310-7.
72. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391-8.
73. Paridaens R, Therasse P, Dirix L, et al. First line homonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) a randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004; 22; (Abstract 515).
74. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 2004; 15: 211-7.
75. Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003; 39: 2318-27.
76. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
77. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93: 456-62.
78. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684-90.
79. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1822.
80. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88.
81. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802-10.
82. Howell A, trialists' Group. A. Effect of anastrozole on bone mineral density: 2-year results of the "arimidex" (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 2003; 82: S27.
83. Duffy SR, Greewood M. The endometrial cancer data from the ATAC (arimidex, tamoxifen, alon or in combination) trial indicates a protective effect of anastrozole (arimidex) upon endometrium. Breast Cancer Res Treat 2003; 82: S29.
84. Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003; 82: S6-S7.
85. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-802.
86. Burstein HJ. Beyond tamoxifen-extending endocrine treatment for early-stage breast cancer. N Engl J Med 2003; 349: 1857-9.
87. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-92.
88. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002; 9(2 Suppl): 9-15.
89. Domont J, Namer M, Khayat D, Spano JP. Neoadjuvant endocrine therapy for breast cancer: an overview. Bull Cancer 2004; 91: 55-62.
90. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527-32.
91. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-16.
92. Smith IE, Dowsett M, trialists I. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor positive (ER+) operable breast cancer in postmenopausal women: IMPACT trial. Breast Cancer Res Treat 2003; 82: S6.
93. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatmenr of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83: 1142-52.
94. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-61.
95. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19: 3357-66.
96. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399-411.
97. Milla-Santos A, Milla L, Porrella J, et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 2003; 26: 317-22.